Cargando…

TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure

BACKGROUND: The current treatment for HIV-1 is based on blocking various stages in the viral replication cycle using combination antiretroviral therapy (ART). Even though ART effectively controls the infection, it is not curative, and patients must therefore continue treatment life-long. AIM: Here w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hvilsom, Caroline Thue, Søgaard, Ole Schmeltz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495198/ https://www.ncbi.nlm.nih.gov/pubmed/34630386 http://dx.doi.org/10.3389/fimmu.2021.704617

Ejemplares similares

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

Strategies for enhancing CAR T cell expansion and persistence in HIV infection
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

CD8 Effector T Cells Function Synergistically With Broadly Neutralizing Antibodies to Enhance Suppression of HIV Infection
por: Veenhuis, Rebecca T., et al.
Publicado: (2021)

Reactivating Immunity Primed by Acellular Pertussis Vaccines in the Absence of Circulating Antibodies: Enhanced Bacterial Control by TLR9 Rather Than TLR4 Agonist-Including Formulation
por: Auderset, Floriane, et al.
Publicado: (2019)

Modeling Kick-Kill Strategies toward HIV Cure
por: Hernandez-Vargas, Esteban A.
Publicado: (2017)

Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans
por: Anderson, Jenna, et al.
Publicado: (2018)

Rhodobacter azotoformans LPS (RAP99-LPS) Is a TLR4 Agonist That Inhibits Lung Metastasis and Enhances TLR3-Mediated Chemokine Expression
por: Murakami, Kaoru, et al.
Publicado: (2021)

Differential Response of Gestational Tissues to TLR3 Viral Priming Prior to Exposure to Bacterial TLR2 and TLR2/6 Agonists
por: Rasheed, Zahirrah B. M., et al.
Publicado: (2020)

Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure
por: Umotoy, Jeffrey C., et al.
Publicado: (2021)

Editorial: Lymph Node T Cell Dynamics and Novel Strategies for HIV Cure
por: Petrovas, Constantinos, et al.
Publicado: (2018)

Fonsecaea pedrosoi Conidia and Hyphae Activate Neutrophils Distinctly: Requirement of TLR-2 and TLR-4 in Neutrophil Effector Functions
por: Breda, Leandro Carvalho Dantas, et al.
Publicado: (2020)

Heterologous COVID-19 vaccination as a strategy to accelerate mass immunization
por: Klastrup, Vibeke, et al.
Publicado: (2022)

Chronic Exposure of Gingival Fibroblasts to TLR2 or TLR4 Agonist Inhibits Osteoclastogenesis but Does Not Affect Osteogenesis
por: Karlis, Gerasimos D., et al.
Publicado: (2020)

TLR10 Senses HIV-1 Proteins and Significantly Enhances HIV-1 Infection
por: Henrick, Bethany M., et al.
Publicado: (2019)

Signaling via TLR2 and TLR4 Directly Down-Regulates T Cell Effector Functions: The Regulatory Face of Danger Signals
por: Zanin-Zhorov, Alexandra, et al.
Publicado: (2013)

A novel defined TLR3 agonist as an effective vaccine adjuvant
por: Ko, Kwang Hyun, et al.
Publicado: (2023)

Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: author's response
por: Søgaard, Ole Schmeltz
Publicado: (2022)

Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine
por: Zhou, Shi-Hao, et al.
Publicado: (2022)

Editorial: Effector functions of therapeutic antibodies
por: Boross, Peter, et al.
Publicado: (2023)

RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine
por: Jangra, Sonia, et al.
Publicado: (2022)

Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis
por: Phelps, Meredith, et al.
Publicado: (2021)

Targeting TRIM5α in HIV Cure Strategies for the CRISPR-Cas9 Era
por: Weatherley, Daryl Anne Victoria, et al.
Publicado: (2017)

Lymph Node Cellular and Viral Dynamics in Natural Hosts and Impact for HIV Cure Strategies
por: Huot, Nicolas, et al.
Publicado: (2018)

Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies
por: Carrillo, Jorge, et al.
Publicado: (2018)

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues
por: Denton, Paul W., et al.
Publicado: (2019)

TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease
por: Mifsud, Edin J., et al.
Publicado: (2014)

TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects
por: Lu, Hailing
Publicado: (2014)

TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection
por: Owen, Allison M., et al.
Publicado: (2021)

Animal Models for HIV Cure Research
por: Policicchio, Benjamin B., et al.
Publicado: (2016)

Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells
por: Fisher, Leigh, et al.
Publicado: (2019)

Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection
por: Khandia, Rekha, et al.
Publicado: (2018)

Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV
por: Gavegnano, Christina, et al.
Publicado: (2019)

Natural Killer Cells in Antibody Independent and Antibody Dependent HIV Control
por: Bernard, Nicole F., et al.
Publicado: (2022)

TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults
por: Offersen, Rasmus, et al.
Publicado: (2012)

Eradication of HIV and Cure of AIDS, Now and How?
por: Zhang, Jielin, et al.
Publicado: (2013)

Targeting the Brain Reservoirs: Toward an HIV Cure
por: Marban, Céline, et al.
Publicado: (2016)

Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production
por: Li, Can, et al.
Publicado: (2018)

Neutralization-Enhancing RF Antibodies for HIV Vaccines
por: Suslov, Konstantin V.
Publicado: (2014)

Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against Shigella spp.
por: Lu, Ti, et al.
Publicado: (2023)

B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis
por: Rijnink, Willemijn F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1irv8feqomg88etg79dmqm9vra